🎥 In this RheumNow Therapeutic Update, Dr. Nicola Dalbeth reviews the latest evidence on the Outcomes of Tophaceous Gout and what every rheumatologist should know. Watch now: https://t.co/KQmkdziLF5 #Gout #Rheumatology #MedEd #SystemicBurdenOfGout https://t.co/h8LhE5XW00

Netherlands pragmatic open-label RCT from 8 rheum centres tested T2T vs Sx Rx in 308 Gout pts starting ULT (87% male; 66 yrs). Remission (no flares & pain < 2) betw 18-24 mos was more in T2T pts (39% vs 24%; p=0.02), but more AE w/ Sx driven Rx (53 vs 42%) https://t.co/5g2dY5y900

Raynauds: Using the Clinical Practice Research Datalink Aurum (PCP) database (1998 - 2023) the prevalence of Raynaud’s 894/100 000, or 158449 cases in 2023. More in elderly & females, less in blacks. Incidence rate 46/100K https://t.co/S5Eg4AZSPU https://t.co/nG2p2g2Jc1

Challenges in Gout Diagnosis Dr. Angelo Gaffo in Birmingham, AL discusses the challenges in diagnosing gout. Presented as part of RheumNow's "Gout: More than Flares" campaign during the month of July 2026. https://t.co/LmTj7cvBGT https://t.co/VRVCrAo2TT

QD CLINIC: Senior Year Gout Daric Mueller, PA-C, discusses a case of difficult-to-treat gout in an individual first diagnosed at age 18 who is now in his early 30s. This QD Clinic is presented as part of RheumNow's "Gout: More than Flares" campaign. https://t.co/9GNk8ZqwyS https://t.co/hAFz6zPcay

Weight loss helps gout, but extreme weight loss (bariatric surgery, ketogenic diets) may trigger gouty attacks. (Not seen with GLP-1 agonist weight loss) For more gout content, follow our Gout: More than Flares campaign at https://t.co/xnBVBN5IXZ, https://t.co/LGEENexSZ6

Subanalysis of SURMOUNT-1 Obesity trial l (2539 pts w/ BMI ≥ 30; tirzepatide vs PBO) showed 21% wt loss by wk 72 w/ TIRZ. Serum uric acid (SUA) decr by -0.69, -0.92, & -0.95 mg/dL on TIRZ (5, 10, & 15 mg qd). Wt loss explained 73% of SUA reduction. https://t.co/V0stEDC4lF https://t.co/t8qNNCrrGM

NEJM Retracts Pivotal ADVOCATE Trial of FDA-Approved Avacopan The New England Journal of Medicine (NEJM) retracted the pivotal study supporting FDA's approval of avacopan (Tavneos) for severe forms of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. https://t.co/GOVyk5poNq

The Power of Self-Management with Chronic Low Back Pain Almost everyone will deal with back pain at some point in their lives. Most recover quickly — but for about 20% of people, acute pain becomes a chronic condition that interferes with daily life and keeps them out of the https://t.co/urZPsVwCV8

Uric Acid: Is Lower Better? There is good evidence that a serum urate less than 6 mg/dL is required to meaningfully reduce urate crystal and gout flare burden, but is even lower better and are there any tradeoffs? https://t.co/yVZOuMhZmr https://t.co/Ldc1pBQThH

< 40% of gout patients are on ULT; <40% of ULT-treated gout patients achieve T2T (SUA < 6.0 mg/dl). For more gout content, follow our Gout: More than Flares campaign at https://t.co/j3iLMZz4HM, https://t.co/zFTozS62me